This section aims to allow rapid communication of innovative early phase clinical trials, where novel scientific ideas are translated to the clinic. These include clinical trials that are distinguished for their novelty in approach, design or indication, timeliness, and unique ability to translate laboratory concepts from the bench to the bedside. Manuscripts are submitted typically at the time a clinical trial has gained full regulatory approval and is being initiated. No clinical results are required. These articles review the background, rationale, clinical design and approach, translational endpoints and expected outcomes of a new clinical trial in a scholarly manner, and provide the opportunity to investigators to share their views and clinical translation efforts with a wide audience at an early stage.
Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV
Many HIV infected individuals with suppressed viral loads experience chronic immune activation frequently developing neurological impairment designated as HIV associated neurocognitive disorder (HAND). Adjunct...